RPA1 and cancer: We discovered 1.05% (63/5993) of the cohort to harbor heterozygous germline RPA1 variants (Figure 1C; Tables 1–3), which was statistically not significant compared to gnomAD non-cancer controls for all cancers and cancer subtypes (Table 4).